Prophylaxis and treatment of Hepatitis B in immunocompromised patients

Alfredo Marzano, Andrea Marengo, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review


The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the treatment with antivirals (therapy) of active carriers, c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive), in order to prevent reverse seroconversion. Moreover it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants, and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined with specific anti-HBV immunoglobulins) in HBsAg-positive candidates and in HBsAg-negative recipients of antiHBc-positive grafts should be adopted.

Original languageEnglish
Pages (from-to)23-50
Number of pages28
JournalHepatitis B Annual
Issue number1
Publication statusPublished - Jan 2008


  • Anti-HBV immunoglobulin
  • AntiHBc
  • Antivirals
  • Chemotherapy
  • HBsAg
  • HBV carrier
  • Hepatitis B virus (HBV)
  • Immunosuppression
  • Lamivudine
  • Prophylaxis.
  • Transplantation

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases


Dive into the research topics of 'Prophylaxis and treatment of Hepatitis B in immunocompromised patients'. Together they form a unique fingerprint.

Cite this